Message: | Therapeutic antibodies designed to block immune checkpoint receptors or activate immune-stimulatory receptors are a potent strategy to treat cancer and function by modulating a patient's own immune system. The combination immunotherapies that associate multiple immune inhibitory receptors, has shown potentially better therapeutic outcomes compared with treatment of a single blockade. Given this, Creative Biolabs has developed a series of Magic™ dual immune checkpoint “humanized” mouse models for in vivo assay of novel combination immunotherapies, including the humanized PD-L1/OX40 dual immune checkpoint knock-in mice. https://www.creative-biolabs.com/drug-discovery/therapeutics/magic-humanized-pd-l1-ox40-dual-immune-checkpoint-knock-in-mice.htm. |